Executive Medical Director, Oncology | Global Head | Novel Therapy for Breast Cancer | NJ/NYC: RETAINED SEARCH

Cornerstone Search Group
Published
September 23, 2019
Location
Greater New York City Area, United States
Category
Job Code
ctmBH2727csg
Contact Email
ctmiras@cornerstonesg.com

Description

Executive Medical Director, Oncology | Lead Global Development | Novel 1st-In- Class Personalized Therapy for Breast Cancer | NJ / NYC Area: RETAINED SEARCH

Position Summary:

In this highly-visible Executive Medical Director role, you will lead the global later-stage development for a novel and 1st-in-class personalized therapy to treat relapsed Breast Cancer where current standard-of-care (SoC) is not effective (note: Breast Cancer patients with this form of relapsed Breast Cancer have a 5-year overall survival rate of less than 25%). You will lead the overall planning and management of the very important Phase 3 Registrational Study/Trial that will start in the 2nd half of 2020, leading to the asset’s NDA filing and expected FDA approval for its initial indication. Subsequent additional indications are expected for this novel and 1st-in-class personalized therapy, both as a mono and as a combination therapy with other inhibitors (in-vivo combination studies have already generated very promising results).

Our Hematology/Oncology MD Specialty Executive Search Practice has been selected and hired by Executive Management on an exclusive basis, working in both a strategic and collaborative arrangement to help them hire the right MD (Hematologist/Oncologist) leader for this executive role.

Confidentiality: All communications are treated as highly confidential information.

Location: Northern NJ / NYC Metro Area (convenient/commutable from NYC, NY State, and many NJ areas)

Relocation Assistance: Relocation package and assistance is available

Attractive Features Include (there are many about the asset, role, company and more):

  • Key Asset: Lead initial indication development for a Novel & 1st-in-class personalized Breast Cancer (BC) mono therapy
  • Important Medicine: Develop a much-needed therapy for patients whose BC relapsed and the current SoC is not effective, i.e. the 5-year survival rate for these patients with relapsed BC is less than 25%
  • Leadership: Lead the Global Project Team responsible for planning and conducting the major Phase 3 registrational study
  • NDA Filing: Lead the development team, and gain valuable NDA filing experience
  • Impact: You will be in a high level and key leadership role where you will be able to make significant contributions to the overall development and successful filing and anticipated approval of a novel therapy
  • Visibility: Report directly to a C-level Sr. Management Team Member, and report N-1 from the President of the Oncology TA
  • Program Management: Lead the development for anticipated additional indications and combination therapies (combing this novel and 1st-in-class mono therapy with other inhibitors that have shown promising in-vivo results)
  • Collegial culture/environment: company prides itself on its science/research based focus and its friendly and collegial working environment
  • Proven Success: join an oncology company with multiple development success (i.e. FDA approvals)
  • 1st Line & Breakthrough: join an oncology company that has developed 1st line & breakthrough cancer therapies
  • In-house R&D: join an oncology company with multiple “in-house” developed successes
  • Pipeline: join a company with multiple early & later-stage assets in addition to its commercialized assets
  • Strategic Collaborations: join an oncology company with an appetite for and a track record of negotiating and managing successful strategic development collaborations
  • R&D Spend: join an oncology company that understands the financial commitment and investment necessary to succeed in the oncology therapeutic area, and that spent over $1 Billion in R&D last year
  • Culture: join an oncology company that has always kept “helping cancer patients” as its primary goal and focus in all its development efforts
  • Best of both worlds: join an established global pharma company that generates billions in annual revenues, invests significantly in its annual R&D spend, creates valuable strategic collaborations, and that maintains a collegial, science focused, and friendly environment with high visibility and access to Sr. Management vs. operating as a large bureaucratic behemoth

Qualifications:

  • MD Hematologist/Oncologist, Board Certification is a plus
  • Several years of experience gained working in industry on the clinical development of oncology assets/therapies
  • Experience with later-stage clinical development studies/trials/programs
  • Strong communication skills
  • Leadership capabilities: experience directly or indirectly leading other professionals as part of a clinical drug development team

Contact:

Courtland T. Miras

Director

Cornerstone Search Group

Life Sciences Executive Search Specialists | Forbes “Top 250 Search Firm” for 2018 & 2017

E: ctmiras@cornerstonesg.com

P: 973-656-0220 x 711

W: cornerstonesg.com

Recent Retained Searches our Hematology/Oncology MD/Physician Specialty Practice Area has successfully completed include *CMO for a Boston-based Early-Stage Oncology Biotech, *SVP & Head of Translational Medicine & Early Clinical Development for a Boston Oncology Biotech, *SVP & Global Head of Oncology Medical Affairs for a Global Oncology Leader, *VP of US Oncology Medical Affairs for an expanding Global Oncology Co, and *Executive Director of Early Clinical Immuno-Oncology Development for a Top 10 Global Immuno-Oncology Co.

Keywords: oncology, cancer, tumor, breast cancer, FDA, NDA, Leadership, estrogen receptor agonist, hormone, endocrine, clinical, project, program, phase, program, retained search, novel, combination

Apply
Drop files here browse files ...
PDF and .doc resume uploads are preferred. docx files are not supported.